• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Related Products
XL147PI3K inhibitor,selective and reversible

XL147

Catalog No. A5112
Size Price Stock Qty
10mM (in 1mL DMSO) $121.00 In stock
5mg $90.00 In stock
25mg $180.00 In stock
100mg $540.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

XL147

Biological Activity

Description XL147 is a selective and reversible inhibitor of PI3Kα/ PI3Kδ/ PI3Kγ with IC50 values of 39 nM/36 nM/23 nM, respectively.
Targets PI3Kα PI3Kδ PI3Kγ PI3Kβ    
IC50 39 nM 36 nM 23 nM 383 nM    

Protocol

Cell experiment [1]:

Cell lines

Rhabdomyosarcoma cell lines, neuroblastoma cell lines

Preparation method

Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

10 nM-100 μM, 6–12 h

Applications

In PPTP cell lines, XL147 (100 μM) demonstrated cytotoxic activity with the IC50 values ranged from 2.7 μM (CHLA-10) to 24.5 μM (TC-71).There was a trend for lower values for the rhabdomyosarcoma panel (median rIC50 5.6 μM) and higher values for the neuroblastoma panel (median rIC50 19.5 μM). XL147 showed higher sensitivity for the rhabdomyosarcoma cell lines and lower sensitivity for the neuroblastoma cell lines.

Animal experiment [1,2]:

Animal models

Solid glioma xenografted mouse model

Dosage form

Oral administration, 100 mg/kg, daily for 14 days

Application

In BALB/c nu/nu mice, Pilaralisib (100 mg/kg, p.o.) induced tumor growth inhibition for solid glioma xenografts. Pilaralisib was well tolerated, with only 0.7% toxicity rate in the treated groups. In athymic female mouse, Pilaralisib (100 mg/kg, p.o.) significantly delayed tumor growth without significant drug-related toxicity.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Reynolds C P, Kang M H, Carol H, et al. Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program[J]. Pediatric blood & cancer, 2013, 60(5): 791-798.

[2]. Chakrabarty A, Sánchez V, Kuba M G, et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors[J]. Proceedings of the National Academy of Sciences, 2012, 109(8): 2718-2723.

XL147 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

XL147 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 956958-53-5 SDF Download SDF
Chemical Name N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide
Canonical SMILES CC1=CC=C(C=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4
Formula C21H16N6O2S2 M.Wt 448.52
Solubility Limited solubility Storage Store at -20°C
General tips N/A
Shipping Condition N/A

Background

XL147 is a potent and orally active inhibitor that targets Class I PI3Ks with IC50 values in the nanomolar level. It has PI3K inhibition activities with IC50 of 39,383,36, and 23nM for PI3Kα, PI3Kβ, PI3Kδ,PI3Kγ, respectively.[1]
PI3Ks are a family of enzymes, which phosphorylate the 3'- OH position of the inositol ring of phosphoinositides.PI3Ks are divided into three classes based on structural features and in vitro lipid substrate specificity. The three class-Ia PI3K (p110 α / β / δ ) and the sole class-Ib PI3K (p110 γ ) couple growth factor receptors and G-protein-coupled receptors, respectively, to a wide range of downstream pathways. Signal transduction via the PI3K/Akt pathway is essential for regulating cellular functions, including proliferation, survival, migration, motility and tumorigenesis, in a variety of cell types. XL147 is a reversible ATP-competitive inhibitor, yet is highly selective against over 130 human protein kinases.[1]
MCF7 and PC-3 cell lines were treated with XL147 led to a reduction in the levels of phosphatidylinositol-3,4,5-tris-phosphate (PIP3) and decline in phosphorylation of AKT and ribosomal S6 protein, which are two downstream effectors of PI3K signaling. Furthermore, XL147 demonstrates potent anti-angiogenic effects in tubule formation driven by vascular endothelial growth factor and potent inhibition of cell migration stimulated by hepatocyte growth factor . [1]
Oral administration of XL147 results in eminent inhibition of tumor growth in mice bearing xenografts in which PI3K signaling is activated, including the PTEN-deficient PC-3 prostate adenocarcinoma and MDA-MB-468 breast adenocarcinoma models, and the K-Ras activated Calu-6 non-small cell lung carcinoma model. These effects on pathway signaling correlate with inhibiting tumor cell proliferation, inhibiting tumor angiogenesis, and inducing apoptosis as determined by immunohistochemical analysis. Moreover, combining XL147 in these models with other mTOR/Raptor inhibitors, such as the chemotherapeutic agents paclitaxel and carboplatin, results in enhanced anti-tumor efficacy associated with a substantial increase in apoptosis when compared to the individual agents alone. [2]
References:
1.Shapiro G, Edelman G, Calvo E, et al. Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavailable PI3K inhibitor[J]. Proc 97th Annu Meet AACR, 2007: 14-18.
2.Traynor A M, Kurzrock R, Bailey H H, et al. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors[J]. J Clin Oncol, 2010, 28(15s): 3078.